Bruker Co. (NASDAQ:BRKR) Receives Consensus Rating of “Hold” from Analysts

Bruker Co. (NASDAQ:BRKR) has been assigned an average rating of “Hold” from the twelve ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $59.11.

Several research firms have recently commented on BRKR. Stifel Nicolaus raised their price objective on shares of Bruker from $48.00 to $65.00 and gave the company a “hold” rating in a research note on Wednesday, February 17th. Wells Fargo & Company lowered shares of Bruker from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $50.00 to $55.00 in a research note on Friday, February 5th. Citigroup raised their price objective on shares of Bruker from $57.00 to $65.00 in a research note on Wednesday, February 17th. Finally, SVB Leerink raised their price objective on shares of Bruker from $50.00 to $70.00 and gave the company an “outperform” rating in a research note on Wednesday, January 27th.

In related news, Director Cynthia M. Friend sold 1,800 shares of the firm’s stock in a transaction that occurred on Monday, March 22nd. The shares were sold at an average price of $60.43, for a total value of $108,774.00. Following the sale, the director now owns 10,486 shares of the company’s stock, valued at $633,668.98. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 26.80% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Global Retirement Partners LLC raised its holdings in Bruker by 28.0% during the fourth quarter. Global Retirement Partners LLC now owns 865 shares of the medical research company’s stock worth $47,000 after purchasing an additional 189 shares in the last quarter. Barclays PLC raised its holdings in Bruker by 2.0% during the fourth quarter. Barclays PLC now owns 10,724 shares of the medical research company’s stock worth $580,000 after purchasing an additional 211 shares in the last quarter. NEXT Financial Group Inc raised its holdings in Bruker by 128.4% during the first quarter. NEXT Financial Group Inc now owns 450 shares of the medical research company’s stock worth $29,000 after purchasing an additional 253 shares in the last quarter. Parallel Advisors LLC raised its holdings in Bruker by 138.4% during the first quarter. Parallel Advisors LLC now owns 441 shares of the medical research company’s stock worth $28,000 after purchasing an additional 256 shares in the last quarter. Finally, Great West Life Assurance Co. Can raised its holdings in Bruker by 3.8% during the third quarter. Great West Life Assurance Co. Can now owns 8,418 shares of the medical research company’s stock worth $335,000 after purchasing an additional 308 shares in the last quarter. 65.89% of the stock is currently owned by institutional investors.

BRKR stock traded down $0.41 during mid-day trading on Tuesday, hitting $68.24. 10,383 shares of the company were exchanged, compared to its average volume of 471,687. The company has a quick ratio of 1.65, a current ratio of 2.67 and a debt-to-equity ratio of 0.86. The firm has a market capitalization of $10.34 billion, a P/E ratio of 67.06, a PEG ratio of 7.11 and a beta of 1.29. The business has a fifty day simple moving average of $65.78 and a 200-day simple moving average of $57.15. Bruker has a 12-month low of $35.98 and a 12-month high of $70.62.

Bruker (NASDAQ:BRKR) last announced its earnings results on Monday, February 15th. The medical research company reported $0.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.02. The company had revenue of $627.50 million during the quarter, compared to analyst estimates of $624.80 million. Bruker had a net margin of 8.04% and a return on equity of 21.78%. Research analysts predict that Bruker will post 1.33 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, March 19th. Investors of record on Friday, March 5th were issued a $0.04 dividend. The ex-dividend date of this dividend was Thursday, March 4th. This represents a $0.16 annualized dividend and a yield of 0.23%. Bruker’s dividend payout ratio (DPR) is 10.19%.

About Bruker

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies.

Recommended Story: What are municipal bonds?

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.